JP2011523945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523945A5 JP2011523945A5 JP2011510650A JP2011510650A JP2011523945A5 JP 2011523945 A5 JP2011523945 A5 JP 2011523945A5 JP 2011510650 A JP2011510650 A JP 2011510650A JP 2011510650 A JP2011510650 A JP 2011510650A JP 2011523945 A5 JP2011523945 A5 JP 2011523945A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- unsubstituted
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3-[(1H-1,2,4-triazol-1-yl) methyl] -2-phenylimidazo [1,2-a] -pyridine Chemical compound 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 229910052805 deuterium Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000005872 benzooxazolyl group Chemical group 0.000 claims 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 206010001488 Aggression Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 102000004300 GABA-A Receptors Human genes 0.000 claims 1
- 108090000839 GABA-A Receptors Proteins 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010049816 Muscle tightness Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 208000012761 aggressive behavior Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- DTKCRSRRCOSFHM-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-(1,2,4-triazol-1-ylmethyl)imidazo[1,2-b]pyridazine Chemical compound C1=CC(Cl)=CC=C1C1=C(CN2N=CN=C2)N2N=CC=CC2=N1 DTKCRSRRCOSFHM-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- WZWIYJLAKMWNGI-UHFFFAOYSA-N 2-methyl-5-[[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]methylsulfanyl]-1,3,4-thiadiazole Chemical compound S1C(C)=NN=C1SCC1=C(C=2C=CC(C)=CC=2)N=C2N1C=C(C)C=C2 WZWIYJLAKMWNGI-UHFFFAOYSA-N 0.000 description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 2
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- OIIOPWHTJZYKIL-PMACEKPBSA-N (5S)-5-[[[5-[2-chloro-3-[2-chloro-3-[6-methoxy-5-[[[(2S)-5-oxopyrrolidin-2-yl]methylamino]methyl]pyrazin-2-yl]phenyl]phenyl]-3-methoxypyrazin-2-yl]methylamino]methyl]pyrrolidin-2-one Chemical compound C1(=C(N=C(C2=C(C(C3=CC=CC(=C3Cl)C3=NC(OC)=C(N=C3)CNC[C@H]3NC(=O)CC3)=CC=C2)Cl)C=N1)OC)CNC[C@H]1NC(=O)CC1 OIIOPWHTJZYKIL-PMACEKPBSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- NBNQOWVYEXFQJC-UHFFFAOYSA-N 2-sulfanyl-3h-thiadiazole Chemical compound SN1NC=CS1 NBNQOWVYEXFQJC-UHFFFAOYSA-N 0.000 description 1
- JQWJOSZRYINDTA-UHFFFAOYSA-N 3-(chloromethyl)-2-(4-chlorophenyl)imidazo[1,2-a]pyridine;hydrochloride Chemical compound Cl.N1=C2C=CC=CN2C(CCl)=C1C1=CC=C(Cl)C=C1 JQWJOSZRYINDTA-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N CC(C)(C(N1C)=O)OC1=O Chemical compound CC(C)(C(N1C)=O)OC1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 0 CC(N1C)=C(*)SC1=O Chemical compound CC(N1C)=C(*)SC1=O 0.000 description 1
- LVHVTYQPRMNICT-UHFFFAOYSA-N CCOC(C=CN1C)=NC1=O Chemical compound CCOC(C=CN1C)=NC1=O LVHVTYQPRMNICT-UHFFFAOYSA-N 0.000 description 1
- UVTUYTIMHXWMRL-UHFFFAOYSA-N CN(C(SC)=NS1)C1=O Chemical compound CN(C(SC)=NS1)C1=O UVTUYTIMHXWMRL-UHFFFAOYSA-N 0.000 description 1
- DHGBSOMRGXWRSE-UHFFFAOYSA-N CN(C)C(C=CN1C)=NC1=O Chemical compound CN(C)C(C=CN1C)=NC1=O DHGBSOMRGXWRSE-UHFFFAOYSA-N 0.000 description 1
- FNRIYKOFDSKGTF-UHFFFAOYSA-N CN(C=CC(N1CCCC1)=N1)C1=O Chemical compound CN(C=CC(N1CCCC1)=N1)C1=O FNRIYKOFDSKGTF-UHFFFAOYSA-N 0.000 description 1
- QXIHJEWUXUZTHM-UHFFFAOYSA-N CN(C=CC([n]1ncnc1)=N1)C1=O Chemical compound CN(C=CC([n]1ncnc1)=N1)C1=O QXIHJEWUXUZTHM-UHFFFAOYSA-N 0.000 description 1
- CVUKXDYMTQWGBD-UHFFFAOYSA-N CN(CC(N1S)=O)C1=O Chemical compound CN(CC(N1S)=O)C1=O CVUKXDYMTQWGBD-UHFFFAOYSA-N 0.000 description 1
- CYSGHNMQYZDMIA-UHFFFAOYSA-N CN(CCN1C)C1=O Chemical compound CN(CCN1C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 1
- MTAUWGJDZIAUQM-UHFFFAOYSA-N CN1N=C(C=CC=C2)N2C1=O Chemical compound CN1N=C(C=CC=C2)N2C1=O MTAUWGJDZIAUQM-UHFFFAOYSA-N 0.000 description 1
- IIFFJWZFJVKHFN-UHFFFAOYSA-N CN1NC2C=CC=CC2C1=O Chemical compound CN1NC2C=CC=CC2C1=O IIFFJWZFJVKHFN-UHFFFAOYSA-N 0.000 description 1
- DBJMEBUKQVZWMD-UHFFFAOYSA-N CN1c(cccc2)c2OCC1=O Chemical compound CN1c(cccc2)c2OCC1=O DBJMEBUKQVZWMD-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridine hydrochloride Substances [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5443208P | 2008-05-19 | 2008-05-19 | |
| US5443708P | 2008-05-19 | 2008-05-19 | |
| US61/054,432 | 2008-05-19 | ||
| US61/054,437 | 2008-05-19 | ||
| PCT/US2009/044525 WO2009143156A2 (en) | 2008-05-19 | 2009-05-19 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090193A Division JP6211556B2 (ja) | 2008-05-19 | 2015-04-27 | イミダゾ［１，２−ａ］ピリジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523945A JP2011523945A (ja) | 2011-08-25 |
| JP2011523945A5 true JP2011523945A5 (cg-RX-API-DMAC7.html) | 2012-07-05 |
| JP5774982B2 JP5774982B2 (ja) | 2015-09-09 |
Family
ID=41031732
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510650A Active JP5774982B2 (ja) | 2008-05-19 | 2009-05-19 | イミダゾ［１，２−ａ］ピリジン化合物 |
| JP2015090193A Active JP6211556B2 (ja) | 2008-05-19 | 2015-04-27 | イミダゾ［１，２−ａ］ピリジン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090193A Active JP6211556B2 (ja) | 2008-05-19 | 2015-04-27 | イミダゾ［１，２−ａ］ピリジン化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8497278B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2300470A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5774982B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009249186B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2724842A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009143156A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200918102A (en) * | 2007-10-24 | 2009-05-01 | Nihon Mediphysics Co Ltd | Novel compound having affinity for amyloid |
| KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도 |
| EP3257854A1 (en) * | 2009-11-05 | 2017-12-20 | University of Notre Dame du Lac | Imidazo[1,2-a]pyridine compounds, synthesis thereof, and methods of using same |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| CA2800618C (en) | 2010-05-26 | 2018-08-28 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| WO2012130322A1 (en) * | 2011-03-31 | 2012-10-04 | Elara Pharmaceuticals Gmbh | Imidazo [1,2-a]pyridine compounds for use in therapy |
| EA027418B1 (ru) | 2011-06-27 | 2017-07-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
| CA2869535A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Pyrrolidino heterocycles |
| ES2855575T3 (es) | 2012-06-26 | 2021-09-23 | Janssen Pharmaceutica Nv | Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos |
| KR102171706B1 (ko) | 2012-07-09 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 포스포디에스테라아제 10 효소의 억제제 |
| JP2016527184A (ja) | 2013-05-24 | 2016-09-08 | イオメット ファーマ リミテッド | Ｓｌｃ２ａ輸送体阻害剤 |
| PE20181352A1 (es) | 2015-09-17 | 2018-08-22 | Marvin J Miller | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias |
| PT3153506T (pt) * | 2015-10-07 | 2018-03-22 | Sanko Tekstil Isletmeleri San Ve Tic As | Isoxazoles, um processo para a sua preparação e seus usos |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3007724C (en) | 2015-12-10 | 2023-10-17 | Bayer Pharma Aktiengesellschaft | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders |
| JP2018538296A (ja) | 2015-12-10 | 2018-12-27 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用 |
| LT3394033T (lt) | 2015-12-22 | 2021-03-10 | Incyte Corporation | Heterocikliniai junginiai, kaip imunomoduliatoriai |
| US20170320875A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HRP20221030T1 (hr) | 2016-06-20 | 2022-11-11 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| CN106279123B (zh) * | 2016-08-15 | 2018-09-04 | 郑州大学 | 3-(苯磺酰甲基)咪唑并杂环类化合物及其合成方法 |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| EA039175B1 (ru) * | 2016-12-14 | 2021-12-14 | Байер Акциенгезельшафт | Замещенные диазагетеробициклические соединения, способ их получения и их применение |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| JP7149276B2 (ja) | 2016-12-22 | 2022-10-06 | インサイト・コーポレイション | Ｐｄ－ｌ１内在化誘導物質としてのテトラヒドロイミダゾ［４，５－ｃ］ピリジン誘導体 |
| BR112019012993A2 (pt) | 2016-12-22 | 2019-12-03 | Incyte Corporation | derivados de benzo-oxazol como imunomoduladores |
| CN107163039A (zh) * | 2017-05-11 | 2017-09-15 | 浙江工业大学 | 一种6‑甲基‑2‑对甲苯基咪唑并[1,2‑a]吡啶‑3‑甲醛的制备方法 |
| JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| MY210070A (en) | 2018-03-30 | 2025-08-25 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| PT3790877T (pt) | 2018-05-11 | 2023-05-10 | Incyte Corp | Derivados de tetrahidro-imidazo[4,5-c]piridina como imunomoduladores pd-l1 |
| PE20210555A1 (es) * | 2018-06-13 | 2021-03-17 | Hoffmann La Roche | Nuevos derivados de isoxazolil eter como pam de gaba a alfa5 |
| CN110964020B (zh) * | 2018-09-28 | 2022-06-14 | 中国科学院大连化学物理研究所 | 一种制备3’,4’-二氢螺[吲哚啉-3,2’-吡咯]化合物的方法 |
| SG11202106706TA (en) * | 2018-12-29 | 2021-07-29 | Wuhan Ll Science And Technology Development Co Ltd | Heterocyclic compound intermediate, preparation method therefor and application thereof |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| BR112022005826A2 (pt) | 2019-09-30 | 2022-06-21 | Incyte Corp | Compostos de pirido[3,2-d]pirimidina como imunomoduladores |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| CN114380819B (zh) * | 2020-10-22 | 2024-08-23 | 鲁南制药集团股份有限公司 | 一种唑吡坦中间体化合物 |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB991589A (en) * | 1963-04-30 | 1965-05-12 | Selvi & C Lab Bioterapico | Novel [1,2-ª‡]imidazopyridines and a process for the manufacture thereof |
| US3489755A (en) * | 1966-08-03 | 1970-01-13 | Pfizer & Co C | Imidazo (1,2-b) pyridazines |
| US4242513A (en) * | 1979-03-05 | 1980-12-30 | Appleton Papers Inc. | Lactone compounds containing a heterocyclic radical |
| GB8305245D0 (en) * | 1983-02-25 | 1983-03-30 | Fujisawa Pharmaceutical Co | Imidazo-heterocyclic compounds |
| FR2568880B1 (fr) * | 1984-08-07 | 1986-12-12 | Synthelabo | Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridines, leur preparation et leur application en therapeutique |
| ATE62687T1 (de) * | 1986-01-22 | 1991-05-15 | Synthelabo | Acylaminomethylimidazo(1,2-a>pyrimidinderivate, ihre herstellung und therapeutische verwendung. |
| WO1989001333A1 (en) * | 1987-08-07 | 1989-02-23 | The Australian National University | IMIDAZO[1,2-b]PYRIDAZINES |
| IN179789B (cg-RX-API-DMAC7.html) * | 1992-02-10 | 1997-12-06 | Council Scient Ind Res | |
| FR2714907B1 (fr) * | 1994-01-07 | 1996-03-29 | Union Pharma Scient Appl | Nouveaux dérivés de l'Adénosine, leurs procédés de préparation, compositions pharmaceutiques les contenant. |
| JPH09176165A (ja) * | 1995-12-25 | 1997-07-08 | Nippon Nohyaku Co Ltd | イミダゾ［１，２−ａ］ピリジン誘導体、その製法およびその用途 |
| US6552037B2 (en) * | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
| US6514969B2 (en) * | 2000-08-16 | 2003-02-04 | Boehringer Ingelheim Pharma Kg | β-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions |
| DE10040016A1 (de) * | 2000-08-16 | 2002-02-28 | Boehringer Ingelheim Pharma | Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| SE0100567D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| DE602004029272D1 (de) * | 2003-10-28 | 2010-11-04 | Sepracor Inc | Imidazoä1,2-aüpyridin-anxiolytika |
| WO2005080355A1 (en) * | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| RU2007121864A (ru) * | 2004-11-11 | 2008-12-20 | Феррер Интернасионал | ИМИДАЗО[1,2-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ), КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРОВ GABAA, ИЛИ α1-GABAA, ИЛИ α2-GABAA (ВАРИАНТЫ) |
| AU2006225355B2 (en) * | 2005-03-21 | 2010-12-09 | Helsinn Healthcare Sa | Imidazo(1,2-a)pyridine derivatives: preparation and pharmaceutical applications |
| US7666880B2 (en) * | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| AU2006254336B9 (en) | 2005-06-01 | 2013-02-28 | Ucb Pharma, S.A. | 2 -oxo-I -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system |
| AU2006278397B2 (en) * | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Oxazolopyridine derivatives as sirtuin modulators |
| AU2006322067A1 (en) * | 2005-12-06 | 2007-06-14 | Merck Sharp & Dohme Corp. | Morpholine carboxamide prokineticin receptor antagonists |
| EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| EP2054060B1 (en) * | 2006-08-24 | 2014-04-02 | Australian Nuclear Science & Technology Organisation | Fluorinated ligands for targeting peripheral benzodiazepine receptors |
| MX2009004700A (es) * | 2006-11-06 | 2009-05-15 | Supergen Inc | Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa. |
| EP1974729A1 (en) * | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2009
- 2009-05-19 AU AU2009249186A patent/AU2009249186B2/en not_active Ceased
- 2009-05-19 JP JP2011510650A patent/JP5774982B2/ja active Active
- 2009-05-19 US US12/993,679 patent/US8497278B2/en not_active Expired - Fee Related
- 2009-05-19 EP EP09751384A patent/EP2300470A2/en not_active Ceased
- 2009-05-19 WO PCT/US2009/044525 patent/WO2009143156A2/en not_active Ceased
- 2009-05-19 CA CA2724842A patent/CA2724842A1/en not_active Abandoned
-
2013
- 2013-06-24 US US13/925,108 patent/US20130289013A1/en not_active Abandoned
-
2015
- 2015-04-27 JP JP2015090193A patent/JP6211556B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523945A5 (cg-RX-API-DMAC7.html) | ||
| ES2769181T3 (es) | Compuestos de piridina y de pirazina sustituidos como inhibidores de PDE4 | |
| CA3011189C (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| JP5966014B2 (ja) | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 | |
| ES2638850T3 (es) | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos | |
| ES2696351T3 (es) | Compuestos de pirazol y su uso como bloqueadores de canales de calcio de tipo T | |
| JP6964576B2 (ja) | 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 | |
| TWI791581B (zh) | 二酮 | |
| JP2020506946A (ja) | がん治療のための２−ヘテロアリール−３−オキソ−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| AU2015298378B2 (en) | Imidazopyridazine compounds | |
| JP2008513498A5 (cg-RX-API-DMAC7.html) | ||
| KR20150107871A (ko) | 티아디아졸 유사체 및 smn-결핍-관련-상태의 치료 방법 | |
| EA015488B1 (ru) | Содержащие диариловый эфир соединения мочевины | |
| JP7744350B2 (ja) | 置換ピラゾロ－ピリミジンおよびその使用 | |
| EA030410B1 (ru) | Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений | |
| CA2988637A1 (en) | Aromatic sulfonamide derivatives | |
| KR20180107232A (ko) | 오렉신 수용체 조정제로서의 할로-치환된 피페리딘 | |
| EP2934536B1 (en) | FACTOR IXa INHIBITORS | |
| CN100572381C (zh) | 吡唑并二氮杂萘衍生物 | |
| US9914727B2 (en) | Factor IXa inhibitors | |
| EP2888259B1 (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease | |
| WO2014069554A1 (ja) | キヌクリジンアミド誘導体及びその医薬用途 | |
| WO2014051055A1 (ja) | キヌクリジンウレア誘導体及びその医薬用途 | |
| HK40075899A (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| HK1206008B (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease |